Edition:
United States

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

4.18USD
4:00pm EDT
Change (% chg)

$0.15 (+3.72%)
Prev Close
$4.03
Open
$4.04
Day's High
$4.18
Day's Low
$4.04
Volume
9,344
Avg. Vol
17,067
52-wk High
$5.70
52-wk Low
$2.35

CRME.OQ

Chart for CRME.OQ

About

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $129.19
Shares Outstanding(Mil.): 31.93
Dividend: --
Yield (%): --

Financials

  CRME.OQ Industry Sector
P/E (TTM): -- 14.12 19.05
EPS (TTM): -0.93 -- --
ROI: -62.46 -6.76 -5.05
ROE: -103.75 -6.22 -4.28

BRIEF-Cardiome announces licensing agreement for xydalba to support planned commercialization in Israel

* Cardiome announces licensing agreement for xydalba™ (dalbavancin hydrochloride) to support planned commercialization in Israel

Jun 21 2017

BRIEF-Cardiome names Justin Renz CFO

* Says Justin Renz joins Cardiome as its new chief financial officer

May 16 2017

BRIEF-Cardiome reports Q1 loss per share $0.20

* Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

May 15 2017

BRIEF-Cardiome announces amendment to term loan agreement with CRG-managed funds

* Cardiome announces amendment to term loan agreement with CRG-managed funds

May 15 2017

BRIEF-Steadymed announces successful completion of trevyent clinical validation study

* Cardiome's partner steadymed announces successful completion of trevyent clinical validation study

Apr 06 2017

BRIEF-Cardiome Pharma's partner SteadyMed receives favorable ruling in USPTO Inter Partes review

* Cardiome Pharma Corp - Cardiome's partner Steadymed Receives favorable ruling in its USPTO inter partes review Source text for Eikon: Further company coverage:

Apr 03 2017

BRIEF-Cardiome's partner SteadyMed receives favorable ruling in its USPTO Inter Partes review

* Cardiome's partner SteadyMed receives favorable ruling in its USPTO Inter Partes review

Apr 03 2017

BRIEF-Cardiome receives Notice of Compliance from Health Canada for its BRINAVESS NDS

* Cardiome receives notice of compliance from Health Canada for its BRINAVESS NDS

Mar 14 2017

BRIEF-Cardiome Pharma Corp says Q4 loss per share $0.18

* Cardiome reports fourth quarter and full year 2016 financial results

Mar 07 2017

BRIEF-Cardiome announces commercial launch of Xydalba(dalbavancin) in France

* Cardiome Pharma Corp - received authorization from French transparency pricing commission to begin selling Xydalba in France

Mar 03 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $133.82 -1.19
Pfizer Inc. (PFE.N) $33.75 -0.02
Novartis AG (NOVN.S) CHF82.00 -0.80
Bayer AG (BAYGn.DE) €121.70 -0.05
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €86.70 --
AstraZeneca plc (AZN.L) 5,240.00 -107.00
GlaxoSmithKline plc (GSK.L) 1,663.50 -34.00
Gilead Sciences, Inc. (GILD.OQ) $71.92 +1.27
Boston Scientific Corporation (BSX.N) $28.12 +0.31

Earnings vs. Estimates